We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
- Authors
Florkowski, Christopher M.; Rowe, Bethan R.; Nightingale, Simon; Harvey, Timothy C.; Barnett, Anthony H.; Florkowski, C M; Rowe, B R; Nightingale, S; Harvey, T C; Barnett, A H
- Abstract
Increased flux through the polyol pathway mediated by the enzyme aldose reductase may be associated with the development of diabetic neuropathy. Fifty-four diabetic patients (median age 56 yr, range 25-65 yr) with chronic neuropathic symptoms were randomly allocated to placebo or aldose reductase inhibition (300 or 600 mg ponalrestat ICI 128436) groups for 24 wk. Patients with vibration perception thresholds (VPTs) greater than 35 V at the great toe or thermal difference thresholds (TTs) greater than 10 degrees C on the dorsum of the foot were excluded from the trial. No significant changes were observed in symptoms of pain, numbness, or paresthesia between ponalrestat and placebo groups, and there were no improvements in VPT or TT at several sites. Posterior tibial nerve conduction velocity changed from 35.3 +/- 4.9 m/s at baseline to 33.4 +/- 4.0 m/s at 24 wk (NS) with placebo compared with 37.6 +/- 5.6 vs. 37.2 +/- 8.7 m/s (NS) with 300 mg ponalrestat and 34.5 +/- 6.1 vs. 36.2 +/- 6.8 m/s (NS) with 600 mg ponalrestat. Further studies are indicated with intervention at an earlier stage in the evolution of neuropathy and for longer periods.
- Subjects
HETEROCYCLIC compounds; COMPARATIVE studies; DIABETIC neuropathies; RESEARCH methodology; MEDIAN nerve; MEDICAL cooperation; OXIDOREDUCTASES; SENSORY perception; RESEARCH; SENSORY neurons; TIBIAL nerve; EVALUATION research; RANDOMIZED controlled trials; CHEMICAL inhibitors
- Publication
Diabetes, 1991, Vol 40, Issue 1, p129
- ISSN
0012-1797
- Publication type
journal article
- DOI
10.2337/diab.40.1.129